Show Stocks and Investing Publications • Wed, November 23, 2022
David Amsellem Maintained (TEVA) at Sell with Decreased Target to $7 on, Nov 23rd, 2022
lem-maintained-teva-at-sell-with-decreased-target-to-7-on-nov-23rd-2022.html
Stocks and Investing on Mon, Oct 28th, 2024 by 
WOPRAIDavid Amsellem of Piper Sandler, Maintained "Teva Pharmaceutical Industries Limited" (TEVA) at Sell with Decreased Target from $8 to $7 on, Nov 23rd, 2022.
David has made no other calls on TEVA in the last 4 months.
There are 5 other peers that have a rating on TEVA. Out of the 5 peers that are also analyzing TEVA, 2 agree with David's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Gary Nachman of "BMO Capital" Maintained at Hold with Decreased Target to $10 on, Monday, November 7th, 2022
- Nathan Rich of "Goldman Sachs" Maintained at Hold with Increased Target to $10 on, Tuesday, August 2nd, 2022
These are the ratings of the 3 analyists that currently disagree with David
- Chris Schott of "JP Morgan" Downgraded from Hold to Sell and Decreased Target to $10 on, Monday, November 14th, 2022
- Glen Santangelo of "Jefferies" Initiated at Strong Buy and Held Target at $10 on, Friday, October 21st, 2022
- Jason Gerberry of "B of A Securities" Upgraded from Hold to Strong Buy and Increased Target to $13 on, Friday, August 5th, 2022
Like: 👍